The effect of marine n-3 polyunsaturated fatty acids on cardiac autonomic and hemodynamic function in patients with psoriatic arthritis: a randomised, double-blind, placebo-controlled trial

Abstract

BackgroundThe aim of this study was to investigate the effect of marine n-3 polyunsaturated fatty acids (PUFA) on cardiac autonomic function and vascular function in patients with psoriatic arthritis.MethodsThe study was conducted as a randomized, double-blind, placebo-controlled trial, where 145 patients with psoriatic arthritis were supplemented with 3 g of n-3 PUFA or olive oil (control) daily for 24 weeks. Blood pressure, heart rate, heart rate variability (HRV), central blood pressure, pulse wave velocity (PWV) and fatty acid composition of granulocytes, were determined at baseline and after supplementation.ResultsAt baseline we found a significant difference in the mean of all normal RR intervals (inverse of heart rate, vary from beat to beat) when comparing subjects with the highest vs the lowest fish intake (p = 0.03). After supplementation for 24 weeks there was a trend towards an increase in RR (p = 0.13) and decrease in heart rate (p = 0.12) comparing the n-3 PUFA group with the control group. However, per-protocol analysis showed significantly increased RR (p = 0.01) and lowered heart rate (p = 0.01) in the n-3 PUFA supplemented patients compared with controls. Blood pressure, PWV and Central blood pressure did not change after supplementation with n-3 PUFA. Adjustment for disease activity and conventional cardiovascular risk factors did not change the results.ConclusionsMarine n-3 PUFA increased RR intervals in patients with psoriatic arthritis which may suggest a protective effect of n-3 PUFA against cardiovascular disease in this population.Trial registrationClinicaltrials.gov Identifier: NCT01818804

A novel biomarker of MMP-cleaved prolargin is elevated in patients with psoriatic arthritis

“…The main findings in this study were: (1) The novel assay was technically robust and specific to the target sequence, (2) the fragment was present in serum and plasma, (3) PROM was upregulated in patients with PsA compared to healthy controls, and (4) PROM did not show a difference in patients treated with PUFA treatment. We investigated the PUFA treatment, as marine n-3 PUFAs have previously reduced inflammation, joint pain, and NSAID use in patients with rheumatoid arthritis (RA), and n-3 PUFA supplementation in patients with PsA led to a reduced use of NSAIDs and paracetamol 33 as well as an improved heart rate and heart rate variability 34 . However, there was no correlation to the disease scores, which we also do not see with PROM.…”

Omega-3 fatty acids correlate with gut microbiome diversity and production of N-carbamylglutamate in middle aged and elderly women

“…The other main omega-3 fatty acid is eicosapentaenoic acid or EPA, and omega-3 levels in humans are estimated by the sum of EPA + DHA with docosapentaenoic acid (DPA) being present at much lower concentrations 4 . Positive effects on health from omega-3 fatty acids have been observed for insulin resistance, adult-onset diabetes mellitus 5 – 7 , hypertension 8 , 9 arthritis 10 , 11 , atherosclerosis 12 , 13 , depression 14 , 15 , thrombosis 16 , some cancers 17 and cognitive decline 18 , 19 .…”

The place of omega-3 and omega-6 acids in supplementary treatment of inflammatory joint diseases

“…All these comorbidities increase the risk of cardiovascular complications, not to mention the risk of dying. It has been shown that the implementation of omega-3 acids in a dose equalling 3 g/day for 24 weeks in patients with PA improves the autonomic and hemodynamic functions of the heart by impacting the value of arterial pressure, the central blood pressure and cardiac function, and reducing the heart rate variability (HRV) and pulse wave velocity (PWV) [39]. This has a direct effect on reducing the risk of cardiovascular complications and the sudden death resulting from these events.…”